Oral Cancer Screening in Workplace: a Cross-sectional Study
Sponsor
Cairo University (Other)
Overall Status
Completed
CT.gov ID
NCT06057857
Collaborator
(none)
302
1
1.9
155.8
Study Details
Study Description
Brief Summary
Employees are to be all screened for oral cancer in work place.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Actual Enrollment
:
302 participants
Observational Model:
Ecologic or Community
Time Perspective:
Cross-Sectional
Official Title:
An Experience of Oral Cancer Screening in Workplace: a Cross-sectional Study
Actual Study Start Date
:
Feb 1, 2023
Actual Primary Completion Date
:
Mar 30, 2023
Actual Study Completion Date
:
Apr 1, 2023
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Employees in Ahram Canadian university
|
Other: conventional oral examination
conventional oral examination
|
Outcome Measures
Primary Outcome Measures
- Presence of lesion: oral cancer or oral potentially malignant lesions [upon study completion; an average of 3 months]
detected on examination
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
- adults
Exclusion Criteria:
- refusal to participate
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ahram Candian University | Giza | Egypt | 12411 |
Sponsors and Collaborators
- Cairo University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Ayat Gamal-AbdelNaser,
Principle investigator,
Cairo University
ClinicalTrials.gov Identifier:
NCT06057857
Other Study ID Numbers:
- ACU-Med2
First Posted:
Sep 28, 2023
Last Update Posted:
Sep 28, 2023
Last Verified:
Sep 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: